Acute coronary syndrome is traditionally classified based on the presence of ST-segment elevation, which is considered a marker of acute coronary artery occlusion. This established paradigm, however, does not always reflect the pathophysiological reality. Current data show that up to 34% of patients with non-ST-segment...
D. A. Ishmaev, A. A. Mironova, D. Duplyakov· The Russian Archives of Inte...· 0 citations
Aim.
To evaluate the potential of high-dose combination lipid-lowering therapy (LLT) in reducing coronary atherosclerosis in patients after acute coronary syndrome (ACS), depending on the presence of vulnerable plaques (VPs).
Material and methods
. The study included 125 patients (men, 68%; mean age, 56,9±9,8...
G. Bikbaeva, A. Kovalskaya, K. Kuznetsova et al.· Russian Journal of Cardiolog...· 0 citations
Objective: To compare two lipid-lowering therapy strategies involving Ezetimibe and Alirocumab on the vulnerability of atherosclerotic plaque (AP) in patients with acute coronary syndrome (ACS) not achieving the LDL-cholesterol target while on intensive statin therapy. Methods: Combi-LLT-ACS (Patients receiving combina...
A. Kovalskaya, G. Bikbaeva, D. Duplyakov et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.